secwatch.observer — SEC 8-K summary
======================================

Issuer:     CRISPR Therapeutics AG (CRSP)
CIK:        0001674416
Form:       8-K
Filed at:   2026-10-19T20:11:18+00:00
Accession:  0001193125-26-425243
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

CRISPR Therapeutics promotes Andrew Silver to CFO as Raju Prasad resigns
------------------------------------------------------------------------

- Andrew J. Silver, 42, was promoted to Chief Financial Officer effective October 19, 2026; he will serve as principal financial and accounting officer.
- Silver's annual salary is $515,000 with a 45% target bonus and a one-time grant of 25,000 restricted stock units vesting on the second anniversary.
- Raju Prasad, Ph.D. resigned as CFO to pursue external opportunities; CRISPR said the resignation was not due to any disagreement and he is expected to stay until on or before November 30, 2026.
- The employment agreement provides six months' notice for involuntary departure, or 12 months plus equity acceleration within 12 months after a Change in Control.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1674416/000119312526425243/0001193125-26-425243-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1674416/000119312526425243/crsp-20261019.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-425243

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer